Barclays
KPTI icon

Barclays’s Karyopharm Therapeutics KPTI Stock Holding History

Barclays’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,400
Closed -$326K – 6947
2017
Q2 		$326K Buy
+2,400
New +$355K ﹤0.01% 3921

Other funds holding KPTI

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Context Capital Management
Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Barclays's KPTI Position: Q3 2026 in Review

Barclays reduced its Karyopharm Therapeutics (KPTI) stake by 83% in Q3 2026, selling an estimated $561K and leaving 28,739 shares worth $35.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4655.

Barclays first reported a position in KPTI in Q4 2013 and has held it in 52 quarters since. The position peaked at $11.1M in Q1 2023. 59 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Barclays held 28,739 shares of Karyopharm Therapeutics worth $35.1K as of Q3 2026.
  • Barclays sold 137,165 Karyopharm Therapeutics shares in Q3 2026, an estimated $561K.
  • Karyopharm Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4655 holding.
  • Barclays first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 52 quarters since.
  • Barclays's Karyopharm Therapeutics position peaked at $11.1M in Q1 2023.
  • 59 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.